JW THERAP-B News

Pharmaron -B (02126) fell 42.80%, now at 1.300 yuan, hitting a 52-week low.

As of 11:34, Wuxi Apptec -B (02126) fell by 42.80% from the previous closing price to 1.300 yuan, hitting a 52-week low; the volume was 0.0227 million shares, with a turnover of 0.0294 million Hong Kong dollars.

金吾財訊Sep 8 23:34 ET

WuXi AppTec-B (02126) granted a total of 2.0391 million share purchase rights and a total of 0.6696 million restricted share units.

WuXi AppTec-B (02126) announced in a notice that on September 2, 2024, in accordance with October 14, 2020...

Zhitong FinanceSep 2 07:31 ET

WuXi Biologics-B (02126) appointed Chen Bingjun as an independent non-executive director.

Pharmaron-B (02126) announced that Chen Bingjun has been appointed as an independent non-executive director, effective from August 2, 2024...

Zhitong FinanceAug 28 07:52 ET

WuXi AppTec Group (02126) released its interim performance, achieving revenue of 86.815 million yuan. Leading product BeiNuoDa has continued to make significant progress in commercialization.

WuXi AppTec-B (02126) released the interim performance for the six months ended June 30, 2024, the group's period...

Zhitong FinanceAug 28 04:59 ET

Express News | JW (Cayman) Therapeutics H1 Revenue RMB 86.8 Million

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Gross Margin 50.4%

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Gross Profit RMB 43.7 Million

ReutersAug 28 04:36 ET

Express News | JW (Cayman) Therapeutics H1 Net Income RMB -240.3 Million

ReutersAug 28 04:36 ET

JW THERAP-B: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024

HKEXAug 28 04:35 ET · Announcements

JW (Cayman) Therapeutics Co. Ltd (HKG:2126) Might Not Be As Mispriced As It Looks After Plunging 27%

Simply Wall StAug 27 19:08 ET

JW Therapeutics Announces NMPA Approval of the Supplemental Biological License Application for Carteyva in Adult Patients With Relapsed or Refractory Mantle Cell Lymphoma

PR NewswireAug 27 05:00 ET

Express News | JW (Cayman) Therapeutics - Nmpa Approved Supplemental Biological License Application for Anti-Cd19 Autologous Chimeric Antigen Receptor T Product

ReutersAug 27 04:37 ET

WuXi AppTec-B (02126.HK) plans to hold a board of directors meeting on August 28th to approve mid-term performance.

On August 14th, Gelonghui reported that Pharma Giant-B (02126.HK) announced that the board of directors' meeting will be held on Wednesday, August 28, 2024, to (including) (i) consider and approve the unaudited interim results of the group for the six months ending June 30, 2024 and their publication; and (ii) handle any other matters.

Gelonghui FinanceAug 14 04:47 ET

Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.

The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.

Zhitong FinanceAug 7 01:50 ET

WuXi AppTec-B (02126.HK) appointed Liu Min as Executive President and Executive Director.

On July 31, Gelonghui -B (02126.HK) announced that Mr. Liu Min has been appointed as the company's Executive President and Executive Director, effective from July 31, 2024. Mr. Liu will lead the group, focusing on innovation, strategic cooperation, excellent operation, and creating long-term value for all stakeholders. Dr. Yiping James Li, the company's Executive Director and Chief Executive Officer, resigned as the company's Executive Director due to his desire to devote more time to his family and other personal interests, effective July 31, 2024. The Board of Directors has reappointed Dr. Li as a non-executive director.

Gelonghui FinanceJul 31 05:57 ET

Express News | JW (Cayman) Therapeutics - Yiping James Li an Executive Director and CEO Resigned as Chief Executive Officer

ReutersJul 31 05:55 ET

Express News | JW (Cayman) Therapeutics - Min Liu Appointed as CEO of Company and as Executive Director

ReutersJul 31 05:55 ET

JW (Cayman) Therapeutics Co. Ltd's (HKG:2126) Shares Leap 26% Yet They're Still Not Telling The Full Story

Simply Wall StJun 7 19:07 ET

Changes in Hong Kong stocks | Pharmaceutical Juno-B (02126) rose more than 8%, SLE clinical data showed good safety

Pharmaceutical Juno-B (02126) rose more than 8%. As of press release, it had risen 8.29% to HK$2.35, with a turnover of HK$2,041,800.

Zhitong FinanceMay 31 02:34 ET

Preliminary Clinical Data on Relma-Cel Injection in Adults With Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

PR NewswireMay 30 06:10 ET